TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis

International Psychogeriatrics

Volumn 26, Issue 6, 2014, Pages 987-994

  Vatsavayi, Anil Varma V ^a,b   Kofler, Julia ^a   Demichele Sweet, Mary Ann A ^a   Murray, Patrick S ^a,b   Lopez, Oscar L ^a   Sweet, Robert A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; psychosis; TDP 43

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; DEATH; DENTATE GYRUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREFRONTAL CORTEX; PSYCHOSIS; TDP 43 PROTEINOPATHY; AGE; BRAIN LEVEL; CHEMISTRY; COMPLICATION; PATHOLOGY; PSYCHOTIC DISORDERS; VERY ELDERLY;

DNA BINDING PROTEIN; PROTEIN TDP-43;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN CHEMISTRY; DENTATE GYRUS; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS;

EID: 84899726647     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610214000246     Document Type: Article

References (40)

1. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimers Disease (1997). Consensus recommendations for the postmortem diagnosis of Alzheimers disease. Neurobiology of Aging, 18, S1-S2.
2. Amador-Ortiz, C., et al. (2007). TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimers disease. Annals of Neurology, 61, 435-445.
3. Ayala, Y. M., et al. (2008). Structural determinants of the cellular localization and shuttling of TDP-43. Journal of Cell Science, 121, 3778-3785.
4. Bigio, E. H., et al. (2010). TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimers disease. Acta Neuropathologica, 120, 43-54.
5. Buratti, E. and Baralle, F. E. (2008). Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Frontiers in Bioscience, 13, 867-878.
6. Chen-Plotkin, A. S., Lee, V. M. and Trojanowski, J. Q. (2010). TAR DNA-binding protein 43 in neurodegenerative disease. Nature Reviews Neurology, 6, 211-220.
7. Davidson, Y. S., et al. (2011). TDP-43 pathological changes in early onset familial and sporadic Alzheimers disease, late onset Alzheimers disease and Downs syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathologica, 122, 703-713.
8. Deutsch, L. H., Bylsma, F. W., Rovner, B. W., Steele, C. and Folstein, M. F. (1991). Psychosis and physical aggression in probable Alzheimers disease. American Journal of Psychiatry, 148, 1159-1163.
9. Emanuel, J. E., et al. (2011). Trajectory of cognitive decline as a predictor of psychosis in early Alzheimers disease in the cardiovascular health study. American Journal of Geriatric Psychiatry, 19, 160-168.
10. Farber, N. B., et al. (2000). Increased neocortical neurofibrillary tangle density in subjects with Alzheimers disease. Archives of General Psychiatry, 57, 1165-1173.
11. Flynn, F. G., Cummings, J. L. and Gornbein, J. (1991). Delusions in dementia syndromes: investigation of behavioral and neuropsychological correlates. Journal of Neuropsychiatry & Clinical Neurosciences, 3, 364-370.
12. Geser, F., et al. (2010). Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Archives of Neurology, 67, 1238-1250.
13. Jeste, D. V., Wragg, R. E., Salmon, D. P., Harris, M. J. and Thal, L. J. (1992). Cognitive deficits of patients with Alzheimers disease with and without delusions. American Journal of Psychiatry, 149, 184-189.
14. Josephs, K. A., et al. (2008). Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology, 70, 1850-1857.
15. Kaufer, D. I., et al. (1998). Assessing the impact of neuropsychiatric symptoms in Alzheimers disease: the Neuropsychiatric Inventory Caregiver Distress Scale. Journal of the American Geriatrics Society, 46, 210-215.
16. Kotrla, K. J., Chacko, R. C., Harper, R. G., Jhingran, S. and Doody, R. (1995). SPECT findings on psychosis in Alzheimers disease. American Journal of Psychiatry, 152, 1470-1475.
17. Lopez, O. L., Wisniewski, S. R., Becker, J. T., Boller, F. and DeKosky, S. T. (1999). Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimers disease. Archives of Neurology, 56, 1266-1272.
18. Mackenzie, I. R., et al. (2009). Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathologica, 117, 15-18.
19. Mega, M. S., Lee, L., Dinov, I. D., Mishkin, F., Toga, A. W. and Cummings, J. L. (2000). Cerebral correlates of psychotic symptoms in Alzheimers disease. Journal of Neurology, Neurosurgery and Psychiatry, 69, 167-171.
20. Mirra, S. S., et al. (1991). The consortium to establish a registry for Alzheimers disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimers disease. Neurology, 41, 479-486.
21. Montine, T. J., et al. (2012). National Institute on Aging-Alzheimers Association guidelines for the neuropathologic assessment of Alzheimers disease: a practical approach. Acta Neuropathologica, 123, 1-11.
22. Murray, P. S., et al. (2012). Beta-amyloid 42/40 ratio and kalirin expression in Alzheimers disease with psychosis. Neurobiology of Aging, 33, 2807-2816.
23. Murray, P. S., Kumar, S., DeMichele-Sweet, M. A. and Sweet, R. A. (in press). Psychosis in Alzheimers disease. Biological Psychiatry. doi: 10.1016/j.biopsych.2013.08.020.
24. Neumann, M., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130-133.
25. Paulsen, J. S., et al. (2000). Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimers disease. Neurology, 54, 1965-1971.
26. Penzes, P. and Remmers, C. (2012). Kalirin signaling: implications for synaptic pathology. Molecular Neurobiology, 45, 109-118.
27. Ropacki, S. A. and Jeste, D. V. (2005). Epidemiology of and risk factors for psychosis of Alzheimers disease: a review of 55 studies published from 1990 to 2003. American Journal of Psychiatry, 162, 2022-2030.
28. Scarmeas, N., et al. (2005). Delusions and hallucinations are associated with worse outcome in Alzheimers disease. Archives of Neurology, 62, 1601-1608.
29. Staff, R. T., Shanks, M. F., Macintosh, L., Pestell, S. J., Gemmell, H. G. and Venneri, A. (1999). Delusions in Alzheimers disease: spet evidence of right hemispheric dysfunction. Cortex, 35, 549-560.
30. Starkstein, S. E., et al. (1994). A SPECT study of delusions in Alzheimers disease. Neurology, 44, 2055-2059.
31. Sultzer, D. L., et al. (1995). The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimers disease. Journal of Neuropsychiatry and Clinical Neurosciences, 7, 476-484.
32. Sweet, R. A., et al. (2000). Psychotic symptoms in Alzheimers disease are not associated with more severe neuropathologic features. International Psychogeriatrics, 12, 547-558.
33. Sweet, R. A., Nimgaonkar, V. L., Devlin, B. and Jeste, D. V. (2003). Psychotic symptoms in Alzheimers disease: evidence for a distinct phenotype. Molecular Psychiatry, 8, 383-392.
34. Sweet, R. A., et al. (2002). Psychosis in Alzheimers disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiology of Aging, 23, 547-553.
35. Sweet, R. A., et al. (2001). The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimers disease. International Psychogeriatrics, 13, 401-409.
36. Tariot, P. N., et al. (1995). The behavior rating scale for dementia of the consortium to establish a registry for Alzheimers disease. American Journal of Psychiatry, 152, 1349-1357.
37. Uryu, K., et al. (2008). Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimers disease and corticobasal degeneration but not in other tauopathies. Journal of Neuropathology & Experimental Neurology, 67, 555-564.
38. Wang, I. F., Reddy, N. M. and Shen, C. K. (2002). Higher order arrangement of the eukaryotic nuclear bodies. Proceedings of the National Academy of Sciences USA, 99, 13583-13588.
39. Wilkosz, P. A., et al. (2010). Trajectories of cognitive decline in Alzheimers disease. International Psychogeriatrics, 22, 281-290.
40. Winton, M. J., Igaz, L. M., Wong, M. M., Kwong, L. K., Trojanowski, J. Q. and Lee, V. M. (2008). Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. Journal of Biological Chemistry, 283, 13302-13309.